From: Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors
Category | Regime | Toxicity | Grade 2 | Grade 3 | Grade 4 | p-value | |||
---|---|---|---|---|---|---|---|---|---|
Neurological | PC | Sensory | 0 | 0% | 0 | 0% | 0 | 0% | 0.002 |
PCV | 10 | 12% | 3 | (4%) | 0 | (0%) | |||
PC | Motor | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0.26 | |
PCV | 3 | (4%) | 0 | (0%) | 0 | (0%) | |||
Gastrointestinal | PC | Nausea | 15 | (25%) | 3 | (5%) | 0 | (0%) | 0.65 |
PCV | 15 | (18%) | 5 | (6%) | 0 | (0%) | |||
PC | Vomiting | 10 | (16%) | 4 | (7%) | 0 | (0%) | 0.62 | |
PCV | 9 | (11%) | 5 | (6%) | 0 | (0%) | |||
Blood/Bone Marrow | PC | WBC | 35 | (57%) | 15 | (25%) | 1 | (2%) | < 0.001 |
PCV | 25 | (30%) | 14 | (17%) | 2 | (2%) | |||
PC | PLT | 10 | (16%) | 8 | (13%) | 2 | (3%) | 0.20 | |
PCV | 8 | (10%) | 6 | (7%) | 1 | (1%) | |||
PC | Hgb | 7 | (11%) | 5 | (8%) | 1 | (2%) | 0.24 | |
PCV | 6 | (7%) | 3 | (4%) | 0 | (0%) | |||
Allergy | PC | Allergy | 6 | (10%) | 0 | (0%) | 0 | (0%) | 0.33 |
PCV | 4 | (5%) | 2 | (2%) | 0 | (0%) |